Clinical trials: ccRCC
Neoadjuvant Therapy
A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC
This trial is a single-center clinical trial to evaluate the tumor shrinkage and safety of tislelizumab combined with axitinib in Neoadjuvant therapy of T2-T3N0M0 renal clear cell carcinoma
- Trial name
- NCT05172440
- Testing
- tislelizumab combined with axitinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hongqian Guo